THE NORMALIZED SMOOTHNESS INDEX AND POPULATION RDH INDEX OF LOSARTANE AND TELMISARTANE IN PATIENTS ...
ŘIHÁČEK, Ivan, Petr FRÁŇA, Daniel SCHWARZ, Martin PLACHÝ and Miroslav SOUČEK. THE NORMALIZED SMOOTHNESS INDEX AND POPULATION RDH INDEX OF LOSARTANE AND TELMISARTANE IN PATIENTS WITH NEWLY DIAGNOSED HYPERTENSION AND METABOLIC SYNDROME. In 20th European meeting on Hypertension, Oslo, 18-21.6.2010. 2010. ISSN 1473-5598. |
Other formats:
BibTeX
LaTeX
RIS
|
Basic information | |
---|---|
Original name | THE NORMALIZED SMOOTHNESS INDEX AND POPULATION RDH INDEX OF LOSARTANE AND TELMISARTANE IN PATIENTS WITH NEWLY DIAGNOSED HYPERTENSION AND METABOLIC SYNDROME. |
Name in Czech | Normalizovaný smoothness index a populační RDH index losartanu a telmisartanu u pacientů s čerstvě zjištěnou hypertenzí a metabolickým syndromem |
Name (in English) | THE NORMALIZED SMOOTHNESS INDEX AND POPULATION RDH INDEX OF LOSARTANE AND TELMISARTANE IN PATIENTS WITH NEWLY DIAGNOSED HYPERTENSION AND METABOLIC SYNDROME. |
Authors | ŘIHÁČEK, Ivan, Petr FRÁŇA, Daniel SCHWARZ, Martin PLACHÝ and Miroslav SOUČEK. |
Edition | 20th European meeting on Hypertension, Oslo, 18-21.6.2010. 2010. |
Other information | |
---|---|
Original language | Czech |
Type of outcome | Conference abstract |
Field of Study | 30201 Cardiac and Cardiovascular systems |
Country of publisher | Czech Republic |
Confidentiality degree | is not subject to a state or trade secret |
WWW | URL |
Impact factor | Impact factor: 3.980 |
Organization unit | Faculty of Medicine |
ISSN | 1473-5598 |
UT WoS | 000283023404270 |
Keywords (in Czech) | smoothness index; RDH index; telmisartan; losartan |
Keywords in English | smoothness index; RDH index; telmisartane; losartane |
Tags | International impact, Reviewed |
Changed by | Changed by: MUDr. Ivan Řiháček, Ph.D., učo 2313. Changed: 17/1/2011 13:02. |
Abstract |
---|
Objective: To determine the normalized smoothness index and the population RDH index of two once daily dosed sartans (losartane, telmisartane) in patients with newly diagnosed hypertension and metabolic syndrome. Design and Methods: Metabolic syndrome and hypertension was defined by ATP III criteria. We evaluated 57 patients in two groups before and after 1 year of treatment with losartane or telmisartane once daily. Results: systolic blood pressure(SBP)normalized smoothness index of losartane was 1,10, telmisartane 0,96, diastolic blood pressure (DBP) normalized smoothness index of losartane was 0,81, telmisartane 0,80. RHP index for SBP for losartane was 24,24,0, for telmisartane 24,24,0, for DBP for losartane 24,24,0, for telmisartane 21,15,2. Cnclusions: losartane have reasonably better homogenous effect on blood pressure than telmisartane. |
Abstract (in English) |
---|
Objective: To determine the normalized smoothness index and the population RDH index of two once daily dosed sartans (losartane, telmisartane) in patients with newly diagnosed hypertension and metabolic syndrome. Design and Methods: BP measurement using mercury sphygmomanometer and 24-hour ambulatory blood pressure monitoring (SpaceLabs 90207) according to the ESH criteria. Metabolic syndrome and hypertension was defined by ATP III criteria. We evaluated 57 patients in two groups before and after 1 year of treatment with losartane or telmisartane once daily. Objective: To determine the normalized smoothness index and the population RDH index of two once daily dosed sartans (losartane, telmisartane) in patients with newly diagnosed hypertension and metabolic syndrome. Design and Methods: BP measurement using mercury sphygmomanometer and 24-hour ambulatory blood pressure monitoring (SpaceLabs 90207) according to the ESH criteria. Metabolic syndrome and hypertension was defined by ATP III criteria. We evaluated 57 patients in two groups before and after 1 year of treatment with losartane or telmisartane once daily. Objective: To determine the normalized smoothness index and the population RDH index of two once daily dosed sartans (losartane, telmisartane) in patients with newly diagnosed hypertension and metabolic syndrome. Design and Methods: BP measurement using mercury sphygmomanometer and 24-hour ambulatory blood pressure monitoring (SpaceLabs 90207) according to the ESH criteria. Metabolic syndrome and hypertension was defined by ATP III criteria. We evaluated 57 patients in two groups before and after 1 year of treatment with losartane or telmisartane once daily. Objective: To determine the normalized smoothness index and the population RDH index of two once daily dosed sartans (losartane, telmisartane) in patients with newly diagnosed hypertension and metabolic syndrome. Design and Methods: Metabolic syndrome and hypertension was defined by ATP III criteria. We evaluated 57 patients in two groups before and after 1 year of treatment with losartane or telmisartane once daily. Results: systolic blood pressure(SBP)normalized smoothness index of losartane was 1,10, telmisartane 0,96, diastolic blood pressure (DBP) normalized smoothness index of losartane was 0,81, telmisartane 0,80. RHP index for SBP for losartane was 24,24,0, for telmisartane 24,24,0, for DBP for losartane 24,24,0, for telmisartane 21,15,2. Cnclusions: losartane have reasonably better homogenous effect on blood pressure than telmisartane. |
Links | |
---|---|
MSM0021622402, plan (intention) | Name: Časná diagnostika a léčba kardiovaskulárních chorob |
Investor: Ministry of Education, Youth and Sports of the CR, Early diagnostics and treatment of cardiovascular diseases |
PrintDisplayed: 24/7/2024 18:16